Accessibility links

Breaking News

Study: Modern AIDS Drugs Add 10 Years of Life Expectancy in Europe, US

FILE - Samples of Nevirapine, an antiretroviral AIDS drug, are displayed at the National Institutes of Health in Memphis, Tenn.
FILE - Samples of Nevirapine, an antiretroviral AIDS drug, are displayed at the National Institutes of Health in Memphis, Tenn.

Life expectancy for young HIV-positive adults has risen by 10 years in the United States and Europe, thanks to improvements in AIDS drugs known as antiretroviral therapy, researchers say.

This means many patients can expect to live as long as those without HIV, according to the researchers' study published Thursday in The Lancet, a medical journal.

The scientists said the improvements were likely to be largely due to the transition to less toxic medicine combinations, with more drug options for people infected with drug-resistant HIV strains, and better adherence to treatment.

"Our research illustrates a success story of how improved HIV treatments coupled with screening, prevention and treatment of health problems associated with HIV infection can extend the lifespan," said Adam Trickey, who led the research at Britain's University of Bristol.

Virus replication blocked

Antiretroviral therapy, or ART, first became widely used in the mid-1990s. It involves a combination of three or more drugs that block the HIV virus' replication. This helps prevent and repair damage to the immune system caused by HIV, and also prevents onward spread of the disease.

The World Health Organization now recommends ART should be given as soon as possible after diagnosis to everyone with HIV.

The researchers analyzed 18 European and North American studies involving 88,504 people with HIV who started ART between 1996 and 2010.

Fewer people who started treatment between 2008 and 2010 died during their first three years of treatment than those who started treatment between 1996 and 2007.

Trickey's team said that when they looked specifically at deaths due to AIDS, the number during treatment declined over time between 1996 and 2010, probably because more modern drugs are more effective in restoring the immune system.

As a result, the researchers said that between 1996 and 2013, the life expectancy of 20-year-olds treated for HIV increased by nine years for women and 10 years for men in the nations of the European Union and North America.

This suggests that life expectancy of a 20-year-old who began ART from 2008 onward and responded well to it would get close to a life expectancy of the general population — 78 years.

Not every patient benefits

But the improvements were not seen in all people with HIV.

Life expectancy of those infected through injecting drugs, for example, did not increase as much as in other groups.

Trickey said this underlined the need for prevention and treatment efforts to be focused on high-risk groups.

  • 16x9 Image


    Reuters is a news agency founded in 1851 and owned by the Thomson Reuters Corporation based in Toronto, Canada. One of the world's largest wire services, it provides financial news as well as international coverage in over 16 languages to more than 1000 newspapers and 750 broadcasters around the globe.